{"doi":"10.1111/bjh.16425","title":"Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients","abstract":"Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0·6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0·4 (95% CI: -0·7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.","journal":"British Journal of Haematology","year":2020,"id":105251,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":23,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9534,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":509737,"name":"Fredrik Ellin","orcid":"0000-0001-9034-5966","position":1,"is_corresponding":false},{"id":509738,"name":"Knut B. Smeland","orcid":"0000-0002-9832-4032","position":2,"is_corresponding":false},{"id":509739,"name":"Tove Wästerlid","orcid":"0000-0002-4281-0349","position":3,"is_corresponding":false},{"id":510815,"name":"Jacob Haaber Christensen","orcid":null,"position":4,"is_corresponding":false},{"id":510816,"name":"Judit Jørgensen","orcid":null,"position":5,"is_corresponding":false},{"id":510817,"name":"Pär Josefsson","orcid":null,"position":6,"is_corresponding":false},{"id":509740,"name":"Andreas Kiesbye Øvlisen","orcid":"0000-0002-4631-9936","position":7,"is_corresponding":false},{"id":509741,"name":"Harald Holte","orcid":"0000-0001-9799-9428","position":8,"is_corresponding":false},{"id":510818,"name":"Yngvild Nuvin Blaker","orcid":null,"position":9,"is_corresponding":false},{"id":510819,"name":"Jacob Handlos Grauslund","orcid":null,"position":10,"is_corresponding":false},{"id":510820,"name":"Jon Bjørn","orcid":null,"position":11,"is_corresponding":false},{"id":509742,"name":"Daniel Molin","orcid":"0009-0005-6662-4865","position":12,"is_corresponding":false},{"id":509743,"name":"Ingemar Lagerlöf","orcid":"0000-0003-3871-014X","position":13,"is_corresponding":false},{"id":404954,"name":"Karin E. Smedby","orcid":"0000-0002-2104-3320","position":14,"is_corresponding":false},{"id":510821,"name":"Katherine Colvin","orcid":null,"position":15,"is_corresponding":false},{"id":491007,"name":"Gita Thanarajasingam","orcid":"0000-0003-2144-5415","position":16,"is_corresponding":false},{"id":239734,"name":"Matthew J. Maurer","orcid":"0000-0002-1867-0526","position":17,"is_corresponding":false},{"id":396925,"name":"Thomas M. Habermann","orcid":"0000-0003-3532-9132","position":18,"is_corresponding":false},{"id":430612,"name":"Kevin Song","orcid":"0000-0003-0786-7961","position":19,"is_corresponding":false},{"id":509744,"name":"Katie Y. Zhu","orcid":"0000-0002-9994-3409","position":20,"is_corresponding":false},{"id":296276,"name":"Alina S. Gerrie","orcid":"0000-0003-4727-1425","position":21,"is_corresponding":false},{"id":509745,"name":"Chan Y. Cheah","orcid":"0000-0001-7988-1565","position":22,"is_corresponding":false},{"id":509746,"name":"Tarec Christoffer El‐Galaly","orcid":"0000-0002-4406-380X","position":23,"is_corresponding":false},{"id":509736,"name":"Lasse Hjort Jakobsen","orcid":"0000-0001-6575-7686","position":0,"is_corresponding":true}],"reference_count":49,"raw_metadata":null,"created_at":"2026-07-18T23:12:17.683386Z","pmid":"32017050","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}